Silicon substituted oxyapatite 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
US2005244449 A1 2005-11-03 [US20050244449]US7498043 B2 2009-03-03 [US7498043] / 2005-11-032009-03-03
申请号/申请日
2005US-11088094 / 2005-03-24
发明人
SAYER MICHAEL;REID JOEL;SMITH TIMOTHY J N;HENDRY JASON;
申请人
MILLENIUM BIOLOGIX;MILLENIUM BIOLOGLX;WARSAW ORTHOPEDIC;
主分类号
IPC分类号
A01N-059/00A01N-059/26A61F-002/00A61F-013/00A61K-009/14A61K-033/00A61K-033/42A61L-024/00A61L-027/12A61L-027/32A61L-027/42A61L-027/46A61L-027/54C01B-015/16C01B-025/32C01B-033/20
摘要
(US7498043) The invention is a silicon substituted oxyapatite compound (Si-OAp) for use as a synthetic bone biomaterial either used alone or in biomaterial compositions.  The silicon substituted oxyapatite compound has the formula Ca5(PO4)3-x(SiO4)xO(1-x)/2, where 0
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2004US-60559956 2004-04-07 2005US-11088094 2005-03-24
主权利要求
(US7498043) What is claimed is: 1.  A silicon substituted oxyapatite compound (Si -- OAp), wherein said compound has the formula Ca5(PO4)3-x(SiO4)xO(1-x)/2, where 0<x<1 .0 and wherein said compound is a synthetic bone biomaterial that is biocompatible in vivo. 2. The compound of claim 1, wherein said compound is provided as a fine or coarse powder, pellets, paste, three-dimensional shaped pieces, macroporous and microporous structures, thin films and coatings. 3. The compound of claim 2, wherein said compound is mixed with one or more calcium phosphate compounds selected from the group consisting of oxyapatite, silicon substituted alpha -tricalcium phosphate, hydroxyapatite, calcium hydroxyapatite, tricalcium phosphate, calcium oxide, alpha-tricalcium phosphate and beta-tricalcium phosphate. 4. The compound of claim 3, wherein said compound is mixed with silicon substituted alpha -tricalcium phosphate. 5. The compound of claim 1, wherein said compound is further provided with an agent selected from the group consisting of calcium carbonate, calcitonin preparations, sex hormones, prostaglandin A1, bisphosphonic acids, ipriflavones, fluorine compounds, vitamin K, bone morphogenetic proteins (BMPs), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF-beta ), insulin-like growth factors 1 and 2 (IGF-1, 2), endothelin, parathyroid hormone (PTH), epidermal growth factor (EGF), leukemia inhibitory factor (LIP), osteogenin, BCSP, bone resorption repressors and mixtures thereof. 6. The compound of claims 1, wherein said compound additionally comprises a bioresorbable polymer. 7. The compound of claim 6, wherein said bioresorbable polymer is selected from the group consisting of collagen, poly-lactic acid, poly-glycolic acid, copolymers of lactic acid and glycolic acid, chitosan, chitin, gelatin and mixtures thereof. 8. The compound of claim 7, wherein said bioresorbable polymer material is reinforced with a particulate form of the Si -- OAp compound or a silicon substituted alpha -tricalcium phosphate compound. 9. A composition to promote bone repair and bone growth, said composition comprising a silicon substituted oxyapatite compound (Si -- OAp), wherein said compound has the formula Ca5(PO4)3-x(SiO4)xO(1-x)/2, where 0<x<1 .0 and wherein said compound is a synthetic bone biomaterial. 10. The composition of claim 9, wherein said compound is provided as a fine or coarse powder, pellets, paste, three-dimensional shaped pieces, macroporous and microporous structures, or thin films and coatings. 11. The composition of claim 9, wherein said compound is mixed with one or more calcium compounds selected from the group consisting of silicon substituted alpha -tricalcium phosphate, oxyapatite, hydroxyapatite, calcium hydroxyapatite, tricalcium phosphate, calcium oxide, alpha-tricalcium phosphate and beta-tricalcium phosphate. 12. The composition of claim 11, wherein said compound is mixed with silicon substituted alpha -tricalcium phosphate. 13. The composition of claim 9, wherein said composition further comprises an agent selected from the group consisting of calcium carbonate, calcitonin preparations, sex hormones, prostaglandin A1, bisphosphonic acids, ipriflavones, fluorine compounds, vitamin K, bone morphogenetic proteins (BMPs), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF-beta ), insulin-like growth factors 1 and 2 (IGF-1, 2), endothelin, parathyroid hormone (PTH), epidermal growth factor (EGF), leukemia inhibitory factor (LIP), osteogenin, BCSP, bone resorption repressors and mixtures thereof. 14. The composition of claim 9, wherein said composition additionally comprises a bioresorbable polymer. 15. The composition of claim 14, wherein said bioresorbable polymer is selected from the group consisting of collagen, poly-lactic acid, poly-glycolic acid, copolymers of lactic acid and glycolic acid, chitosan, chitin, gelatin and mixtures thereof. 16. The composition of claim 15, wherein said bioresorbable polymer material additionally comprises a particulate form of the Si -- OAp compound or a silicon substituted alpha -tricalcium phosphate compound. 17. A method for making a silicon substituted oxyapatite of the formula Ca5(PO4)3-x(SiO4)xO(1-x/2, where 0<x<1.0, said method comprising: mixing a calcium phosphate colloidal suspension with a finely dispersed, fumed silica;  while maintaining a ratio of Ca/(P+Si) at about 1.67 in said mixture;  and sintering for about 1 hour at a temperature of about 800 deg. C. to about 1200 deg. C. under vacuum. 18. The method of claim 17, wherein said temperature is about 1000 deg. C. to about 1200 deg. C. 19. The method of claim 18, wherein said temperature is about 1175 deg. C. 20. The method of claim 17, wherein said vacuum is about 5 * l0-4 torr to about 1 * 10 -5 torr. 21. The method of claim 17, wherein said silicon is provided at a concentration of between about 0.5 mol SiO2: mol HA to about 1.5 mol SiO2: mol HA. 22. The method of claim 17, wherein said silicon is provided at a concentration of about 2.6 to 7.1 wt % silicon. 23. A method for the treatment of bone-related clinical conditions selected from the group consisting of an orthopedic, maxillo-facial and dental defect, the method comprising providing a silicon substituted oxyapatite compound (Si -- OAp) of claim 1 wherein the compound is provided to said defect as a fine or coarse powder, pellets, three-dimensional shaped pieces, macroporous structures, thin films and coatings. 24. A method for substituting natural bone at sites of skeletal surgery in human and animal hosts with a silicon substituted oxyapatite compound (Si -- OAp), wherein said compound has the formula Ca5(PO4)3-x(SiO4)xO(1-x)/2, where 0<x<1.0, the method comprising the steps of: implanting said Si -- OAp compound at the site of skeletal surgery wherein such implantation promotes the formation of new bone tissue at the interfaces between the compound and said host. 25. The method of claim 23, wherein said compound is provided as a fine or coarse powder, pellets, paste, three-dimensional shaped pieces, macroporous and microporous structures, thin films and coatings. 26. The method of claim 23, wherein said compound is mixed with one or more calcium compounds selected from the group consisting of oxyapatite, a silicon substituted alpha -tricalcium phosphate, hydroxyapatite, calcium hydroxyapatite, tricalcium phosphate, calcium oxide, alpha-tricalcium phosphate and beta-tricalcium phosphate. 27. The method of claim 23, wherein said compound is further provided with an agent selected from the group consisting of calcium carbonate, calcitonin preparations, sex hormones, prostaglandin A1, bisphosphonic acids, ipriflavones, fluorine compounds, vitamin K, bone morphogenetic proteins (BMPs), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF-beta ), insulin-like growth factors 1 and 2 (IGF-1, 2), endothelin, parathyroid hormone (PTH), epidermal growth factor (EGF), leukemia inhibitory factor (LIP), osteogenin, BCSP, bone resorption repressors and mixtures thereof. 28. The method of claim 23, wherein said compound additionally comprises a bioresorbable polymer. 29. The method of claim 28, wherein said bioresorbable polymer is selected from the group consisting of collagen, poly-lactic acid, poly-glycolic acid, copolymers of lactic acid and glycolic acid, chitosan, chitin, gelatin and mixtures thereof. 30. The method of claim 28, wherein said bioresorbable polymer material is reinforced with a particulate form of the Si -- OAp compound, a and/or a silicon substituted alpha -tricalcium phosphate compound compound.
法律状态
(US7498043) LEGAL DETAILS FOR US2005244449  Actual or expected expiration date=2026-06-24    Legal state=ALIVE    Status=GRANTED     Event publication date=2005-03-24  Event code=US/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=US US11088094  Application date=2005-03-24  Standardized application number=2005US-11088094     Event publication date=2005-03-24  Event code=US/EXMR  Event type=Administrative notifications  USPTO Examiner Name Primary Examiner: ARNOLD, ERNST V    Event publication date=2005-03-24  Event code=US/ART  Event type=Administrative notifications  USPTO Art Group  ART=1616     Event publication date=2005-03-24  Event code=US/ENT  Event type=Administrative notifications  Entity Status Set to Undiscounted Business Entity Status: UNDISCOUNTED    Event publication date=2005-03-24  Event code=US/AIA  Event type=Administrative notifications  First Inventor File Indicated:  AIA=No     Event publication date=2005-03-24  Event code=US/DK  Event type=Examination events  Attorney Docket Number Docket Nbr: 7479-112 LAB    Event publication date=2005-03-24  Event code=US/CUST  Event type=Examination events  Attorney/Agent Customer Number Customer Nbr: 62644    Event publication date=2005-05-18  Event code=US/INCD  Event type=Examination events  Event type=OAO  Notice Mailed--Application Incomplete--Filing Date Assigned    Event publication date=2005-09-21  Event code=US/IDS  Event type=Examination events  Event type=OAI  Information Disclosure Statement Filed    Event publication date=2005-11-03  Event code=US/A1  Event type=Examination events  Application published  Publication country=US  Publication number=US2005244449  Publication stage Code=A1  Publication date=2005-11-03  Standardized publication number=US20050244449     Event publication date=2005-11-17  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner    Event publication date=2006-03-15  Event code=US/IDS  Event type=Examination events  Event type=OAI  Information Disclosure Statement Filed    Event publication date=2006-03-21  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner    Event publication date=2007-04-10  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment  Effective date of the event=2005-05-06  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNORS:SAYER, MICHAEL REID, JOEL SMITH, TIMOTHY J.N. AND OTHERS REEL/FRAME:019150/0368     Event publication date=2007-04-16  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment  Effective date of the event=2007-04-05  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNOR:INSIGNIA ENERGY INC. REEL/FRAME:019161/0704     Event publication date=2007-04-19  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment  Effective date of the event=2007-04-16  CONFIRMATORY ASSIGNMENT ASSIGNORS:SAYER, MICHAEL REID, JOEL SMITH, TIMOTHY J.N. AND OTHERS REEL/FRAME:019210/0281     Event publication date=2007-04-19  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment  Effective date of the event=2006-12-18  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNOR:MILLENIUM BIOLOGIX INC. REEL/FRAME:019204/0739     Event publication date=2007-05-22  Event code=US/RESTREQ  Event type=Examination events  Event type=Corrections  Event type=OAO  Restriction/Election Requirement    Event publication date=2007-08-21  Event code=US/ELC  Event type=Examination events  Event type=OAI  Response to Election / Restriction Filed    Event publication date=2007-08-21  Event code=US/136G  Event type=OAO  Request for Extension of Time - Granted    Event publication date=2007-10-04  Event code=US/CTNF  Event type=Examination events  Event type=OA  Event type=OAO  Non-Final Rejection    Event publication date=2007-11-01  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment  Effective date of the event=2007-05-08  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNOR:MILLENIUM BIOLOGIX TECHNOLOGIES, INC. REEL/FRAME:020054/0382     Event publication date=2008-01-03  Event code=US/CTNFR  Event type=Examination events  Event type=OAI  Response after Non-Final Action    Event publication date=2008-03-31  Event code=US/EXAC  Event type=Examination events  Event type=OAO  Examiner's Amendment Communication    Event publication date=2008-07-01  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner    Event publication date=2008-07-07  Event code=US/NOAM  Event indicator=Pos  Event type=Examination events  Event type=OAO  Mail Notice of Allowance    Event publication date=2008-08-18  Event code=US/M327  Event type=Examination events  Event type=OAO  Miscellaneous Communication to Applicant - No Action Count    Event publication date=2008-09-15  Event code=US/EXAC  Event type=Examination events  Event type=OAO  Examiner's Amendment Communication    Event publication date=2008-10-03  Event code=US/ENT  Event type=Administrative notifications  Entity Status Set to Undiscounted    Event publication date=2009-01-22  Event code=US/APRDY  Event indicator=Pos  Event type=Examination events  Application Is Considered Ready for Issue    Event publication date=2009-02-11  Event code=US/PAT  Event indicator=Pos  Event type=Event indicating In Force  Patented Case    Event publication date=2009-02-11  Event code=US/ISSM  Event indicator=Pos  Event type=Examination events  Event type=OAO  Event type=Restitution or restoration  Issue Notification Mailed    Event publication date=2009-03-03  Event code=US/B2  Event indicator=Pos  Event type=Event indicating In Force  Granted patent as second publication  Publication country=US  Publication number=US7498043  Publication stage Code=B2  Publication date=2009-03-03  Standardized publication number=US7498043     Event publication date=2009-03-03  Event code=US/354  Event indicator=Pos  Event type=Extension of term of duration of protection  Patent term extended under  35 U.S.C 154(b) until/for Delays (A,B,C): 457  Overlap Delays: 0  Non Overlap Delays: 457   PTO Office Delays: 0  Applicant Delays: 0  Adjustment total:  Number of days of extension=457    Event publication date=2012-03-13  Event code=US/NMFP  Event type=Payment or non-payment notifications  Publication of First Notice of Maintenance Fees Payable. PAYMENT NOTICE YEAR:  Year of payment of annual fees=3     Event publication date=2012-09-04  Event code=US/FPAY  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Fee payment recorded   Annual fees payment date=2012-09-04     Year of payment of annual fees=4     Event publication date=2016-03-15  Event code=US/NMFP  Event type=Payment or non-payment notifications  Publication of First Notice of Maintenance Fees Payable. PAYMENT NOTICE YEAR:  Year of payment of annual fees=7     Event publication date=2016-09-06  Event code=US/FPAY  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Fee payment recorded   Annual fees payment date=2016-09-06     Year of payment of annual fees=8
专利类型码
A1B2
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部